751 related articles for article (PubMed ID: 25093263)
1. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
[TBL] [Abstract][Full Text] [Related]
2. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
Li X; Niu QT; Warmington KS; Asuncion FJ; Dwyer D; Grisanti M; Han CY; Stolina M; Eschenberg MJ; Kostenuik PJ; Simonet WS; Ominsky MS; Ke HZ
Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
Tian X; Jee WS; Li X; Paszty C; Ke HZ
Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
[TBL] [Abstract][Full Text] [Related]
4. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
5. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
Ma YL; Hamang M; Lucchesi J; Bivi N; Zeng Q; Adrian MD; Raines SE; Li J; Kuhstoss SA; Obungu V; Bryant HU; Krishnan V
Bone; 2017 Apr; 97():20-28. PubMed ID: 27939957
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis.
Virdi AS; Irish J; Sena K; Liu M; Ke HZ; McNulty MA; Sumner DR
J Bone Joint Surg Am; 2015 Jan; 97(2):133-40. PubMed ID: 25609440
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
8. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
Wu J; Cai XH; Qin XX; Liu YX
Z Gerontol Geriatr; 2018 Jul; 51(5):550-556. PubMed ID: 28364259
[TBL] [Abstract][Full Text] [Related]
9. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
Ominsky MS; Niu QT; Li C; Li X; Ke HZ
J Bone Miner Res; 2014 Jun; 29(6):1424-30. PubMed ID: 24967455
[TBL] [Abstract][Full Text] [Related]
10. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
[TBL] [Abstract][Full Text] [Related]
12. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats.
Liu Y; Rui Y; Cheng TY; Huang S; Xu L; Meng F; Lee WY; Zhang T; Li N; Li C; Ke H; Li G
Calcif Tissue Int; 2016 Mar; 98(3):263-74. PubMed ID: 26603303
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
Zhang D; Hu M; Chu T; Lin L; Wang J; Li X; Ke HZ; Qin YX
Bone; 2016 Jun; 87():161-8. PubMed ID: 26868528
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
16. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis.
Chen H; Xu X; Liu M; Zhang W; Ke HZ; Qin A; Tang T; Lu E
Bone; 2015 Jul; 76():141-8. PubMed ID: 25868799
[TBL] [Abstract][Full Text] [Related]
18. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
Kostenuik PJ; Smith SY; Jolette J; Schroeder J; Pyrah I; Ominsky MS
Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats.
McDonald MM; Morse A; Mikulec K; Peacock L; Yu N; Baldock PA; Birke O; Liu M; Ke HZ; Little DG
J Orthop Res; 2012 Oct; 30(10):1541-8. PubMed ID: 22457198
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
